HOME >> BIOLOGY >> NEWS
UM Cancer researchers test custom-made vaccine for non-Hodgkin's lymphoma

As part of a national multi-center study, researchers at the University of Maryland Greenebaum Cancer Center in Baltimore are testing a custom-made vaccine for low-grade non-Hodgkins lymphoma that uses each patients own tumor cells to combat the cancer.

This type of low-grade follicular lymphoma has traditionally been highly treatable, but essentially incurable, says Aaron P. Rapoport, M.D., the director of lymphoma-gene medicine at the Greenebaum Cancer Center and the chief investigator for the study. This technique for harnessing the immune system may result in long-term disease remission and potential cures for some patients.

So far, four people have been enrolled in the study at the Greenebaum Cancer Center, but researchers hope to recruit a total of 12 to 15 patients in the Phase III clinical trial. The first patient to be vaccinated, a 45-year-old Baltimore woman, started her treatment earlier this month after completing a course of chemotherapy.

About 480 patients are expected to participate in the nationwide study at 25 institutions in the United States and Canada. The study is sponsored by Genitope Corporation, a California-based biotechnology company developing new therapies for treating cancer.

To be eligible for the study, patients must have been diagnosed with follicular lymphoma, a common form of cancer of the lymphatic system, and have not yet received treatment. If enrolled, they will have a small biopsy taken of their cancer, either from a lymph node or bone marrow, which will be sent to Genitope Corporation to make a vaccine unique to each patient.

The customized vaccine is designed to target a tumor-specific marker, or idiotype, which, like a fingerprint, is unique to every lymphoma patient. Once injected, the vaccine is intended to activate the immune system to attack cells that have the idiotype protein on their surface, namely the cancer cells.


'"/>

Contact: Karen E. Warmkessel
kwarmkessel@umm.edu
410-328-8919
University of Maryland Medical Center
23-Apr-2002


Page: 1 2 3

Related biology news :

1. Cancer vaccine based on pathogenic listeria bacteria shows promise targeting metastases
2. 16th EORTC NCI AACR Symposium Molecular Targets and Cancer Therapeutics
3. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
4. Cancer gene MYC emerging as key research target
5. Cancer patient, heal thyself
6. USC researcher named General Motors Cancer Research Scholar
7. Fox Chase Cancer Centers Alfred Knudson Jr. named 2004 Kyoto Prize winner
8. Wilex & Fox Chase Cancer Center begin trial w/ novel compound targeting tumor invasion & metastasis
9. Cancer drug resistance research leads to possible therapeutic target for Alzheimers disease
10. Fox Chase Cancer Center research shows kidney cancer can be diagnosed in urine
11. National Cancer Gene Therapy Foundation gives $4.0 million in research grants

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/22/2018)... , ... September 20, 2018 , ... ... version of NovoExpress® software which supports the recently launched NovoCyte ... NovoCyte® flow cytometer and NovoSampler® Pro products. , In addition ...
(Date:9/15/2018)... ... 14, 2018 , ... Today, Mediaplanet announces the launch of ... being done within rare diseases research, diagnostics, and will highlight what industry experts ... , The print component of "Rare Diseases" is distributed within ...
(Date:9/7/2018)... ... September 05, 2018 , ... Following ... manufacturing facility late last year, IPS-Integrated Project Services, LLC and G-CON Manufacturing have ... cell therapies. The iCON solution provides a pre-fabricated modular cleanroom infrastructure for the ...
Breaking Biology News(10 mins):
(Date:8/29/2018)... Calif. (PRWEB) , ... August 28, 2018 , ... ... scientists from around the world, is proud to announce the launch of a new ... offers for a chance to win one of LabRoots most popular shirts. , Throughout ...
(Date:8/23/2018)... , ... August 22, 2018 , ... ... for Android on September 1st, making it the first fully-featured app for electronic ... Android devices. Combined, iOS and Android constitute 99 percent of the market share ...
(Date:8/17/2018)... ... , ... The opening of the new Titusville facility marks the completion of ... had a well established local presence, servicing the Space Coast since 1972. Astro Pak ... ongoing work at the Mobile Launch Platform (MLP) in support of NASA’s upcoming Space ...
(Date:8/14/2018)... ... 2018 , ... Labconco Corporation manufactures laboratory equipment, specializing in ... Labconco produces other lab equipment, such as glassware washers and freeze dryers. Labconco ... in design and manufacturing. , Through this webinar, which is sponsored by ...
Breaking Biology Technology:
Cached News: